Supporting the "Healthy China" Strategy: Health Yuan's "Wu Shu®" Makes a Significant Appearance at the 2020 China Respiratory Forum
Published Time:
2020-08-21
The sudden outbreak of the novel coronavirus pneumonia in 2020 brought increased national attention to the respiratory field. In fact, chronic respiratory diseases have become one of the three most common chronic diseases in China. Statistics show that there are approximately 45.7 million asthma patients and 100 million COPD patients in China. In 2018, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Healthy Yuan Pharmaceutical Group") launched a chronic disease poverty alleviation project and has continued to pay close attention to people's livelihood, undertaking social responsibility based on its own advantages, and striving to practically and accurately implement the "Healthy China" initiative.
On August 15, 2020, Healthy Yuan Pharmaceutical Group, as the donor, was invited by the China Health Promotion Foundation to participate in Anhui "Healthy Anhui, Enjoy Breathing" 2020 China Respiratory Forum - Anhui Sub-forum actively participating in the exchange and discussion of hot topics on respiratory disease treatment drugs and disease management.
At this forum, Healthy Yuan Group's new nebulized inhalation product - 0.5mg Budesonide Suspension for Inhalation (Wu Shu®) made a significant appearance as the first domestically produced small-specification budesonide to pass the consistency evaluation (Approval Number: Guo Yao Zhun Zi H20203343), it became a highlight of the forum.
It is reported that, "Wu Shu®" is suitable for the treatment of bronchial asthma and can replace or reduce the treatment with oral steroids. Inhalation therapy is the preferred treatment for asthma and other respiratory diseases. Inhaled drugs can directly reach the respiratory tract and lungs, with advantages such as rapid onset, small dosage, and minimal side effects. At the same time, Wu Shu® is the first small-specification budesonide to pass the consistency evaluation. In terms of quality, it strictly controls production requirements, and the impurity content after six months of storage is about 15% lower than the original research, with better stability; in terms of efficacy, the effective deposition particle size is consistent with the original research, ensuring excellent lung deposition effect. As a high-quality domestic generic drug, the launch of Wu Shu® provides a better choice for the treatment and management of a wide range of respiratory disease patients.
Zhu Baoguo, chairman of Healthy Yuan Pharmaceutical Group, has always emphasized innovation-driven development, attaches importance to research and development innovation, and has deeply deployed inhalation products, challenging the inhalation market monopolized by foreign companies. In 2019, Healthy Yuan Pharmaceutical Group obtained registration certificates for inhalation compound ipratropium bromide solution (Shutanlin) and salbutamol hydrochloride nebulized inhalation solution (Lishutong). This July, the new product 0.5mg budesonide suspension for inhalation (Wu Shu) was launched, providing high-quality and safe drug options for more than 100 million asthma and chronic obstructive pulmonary disease patients in China.
Healthy Yuan Pharmaceutical Group has a diversified and multi-layered R&D team, accurately positioning R&D, breaking through high R&D barriers, and focusing on building technology platforms such as monoclonal antibodies, inhalation preparations, long-acting sustained-release microspheres, and nanolipid microemulsions, combining imitation and innovation, and paying particular attention to the R&D and updating of inhalation products. Following "Shutanlin®" and "Lishutong®", the domestic market welcomes another new domestic product, "Wu Shu®", which has milestone significance for the R&D and updating of domestic inhalation generic drugs, further demonstrating the company's R&D competitiveness.
This China Respiratory Forum focuses on the long-term management of chronic diseases, advocating for effective long-term chronic disease management and related knowledge education for patients, which is highly consistent with the national "Healthy China" strategic thinking.
In fact, since 2018, Healthy Yuan has successively carried out chronic disease poverty alleviation projects in poverty-stricken areas such as Zhaotien District, Guangyuan City, Sichuan Province; Songpan County, Aba Tibetan and Qiang Autonomous Prefecture, Sichuan Province; Hunyuan County, Datong City, Shanxi Province; Tianzhu Tibetan Autonomous County, Gansu Province; and Xianghai National Nature Reserve, Jilin Province. By December 2019, a total of 9 poverty-stricken areas had signed assistance agreements, benefiting more than 500 families with chronic diseases. In June 2020, Healthy Yuan and Lizhu Pharmaceutical Group reached a chronic disease poverty alleviation agreement with Pingwu County, and the first batch of high-value medicines for hyperlipidemia, hypertension, and cardiovascular and cerebrovascular diseases worth 1 million RMB were successively distributed free of charge to poor households with chronic diseases in Pingwu County, bringing them health and love.
In the future, Healthy Yuan Pharmaceutical Group will continue to actively respond to the call of "Healthy China", addressing the urgent needs of the people, tirelessly exploring sustainable paths for national health, and contributing to the implementation of the Outline of the "Healthy China 2030" Plan.